Press Releases
August 13, 2024
Panbela Provides Business Update and Reports Q2 2024 Financial Results
July 30, 2024
Panbela to Host Q2 2024 Earnings Conference Call on 8/13/24
June 24, 2024
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial
DSMB Recommended Continuation with No Trial Modification
- DSMB Recommends Continuation without Modification for Third Time
- Safety Review Included 395 Patients
- Interim Survival Analysis Still Expected Early 2025 given Lower-Than-Expected Event Rate
- Low Event Rate Suggests Potential for Prolonged Survival
- Rapid Enrollment Positions Company for Enrollment Completion by Q1 2025; Earlier Than Expected
June 10, 2024
Panbela Announces Oral Presentation at Digestive Disease Week (DDW)
Evaluation of the Safety and Efficacy of Eflornithine (Difluoromethylornithine, DFMO) in Patients with Gastric Premalignant Conditions in the High Incidence Areas of Latin America
May 15, 2024
Panbela Provides Business Update and Reports Q1 2024 Financial Results
May 6, 2024
Panbela Announces Issuance of New US & Canada Patent for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
May 1, 2024
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
April 30, 2024
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week (DDW)
April 22, 2024
Panbela Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
Trial’s lower-than-expected event rate suggests improved survival outcomes
April 18, 2024
Panbela Announces Poster Presentation at American Association for Cancer Research
Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovarian cancer models
View/download poster presentation »